AbbVie Inc. $ABBV Shares Bought by Torray Investment Partners LLC

Torray Investment Partners LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 267.7% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 95,042 shares of the company’s stock after acquiring an additional 69,195 shares during the period. AbbVie makes up approximately 2.6% of Torray Investment Partners LLC’s portfolio, making the stock its 13th largest position. Torray Investment Partners LLC’s holdings in AbbVie were worth $17,642,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Brighton Jones LLC grew its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its holdings in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after purchasing an additional 3,064 shares in the last quarter. REDW Wealth LLC lifted its holdings in AbbVie by 5.9% during the first quarter. REDW Wealth LLC now owns 1,299 shares of the company’s stock valued at $272,000 after purchasing an additional 72 shares in the last quarter. Lee Danner & Bass Inc. lifted its holdings in AbbVie by 0.7% during the first quarter. Lee Danner & Bass Inc. now owns 19,693 shares of the company’s stock valued at $4,126,000 after purchasing an additional 136 shares in the last quarter. Finally, McGlone Suttner Wealth Management Inc. lifted its holdings in AbbVie by 8.0% during the first quarter. McGlone Suttner Wealth Management Inc. now owns 11,044 shares of the company’s stock valued at $2,314,000 after purchasing an additional 818 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In other AbbVie news, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the sale, the executive vice president directly owned 58,247 shares in the company, valued at $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares of the company’s stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on ABBV shares. Wall Street Zen raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Morgan Stanley increased their price objective on shares of AbbVie from $250.00 to $255.00 and gave the company an “overweight” rating in a report on Friday, August 1st. UBS Group set a $251.00 price target on shares of AbbVie in a research note on Friday, October 3rd. Bank of America raised their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Finally, Piper Sandler raised their price target on shares of AbbVie from $231.00 to $284.00 and gave the stock an “overweight” rating in a research note on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $234.80.

AbbVie Price Performance

AbbVie stock opened at $218.14 on Monday. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $244.81. The stock has a market cap of $385.35 billion, a P/E ratio of 103.87, a PEG ratio of 1.42 and a beta of 0.51. The company has a 50-day moving average price of $222.42 and a 200 day moving average price of $201.15. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the business earned $3.00 earnings per share. AbbVie’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio (DPR) is 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.